ResMed Q2 2017 Investor Presentation

ResMed investor presentation from January 2017 detailing the company's strategy for sleep apnea, COPD, and neuromuscular disease treatment. Highlights growth opportunities in underpenetrated markets and ResMed's commitment to innovation, operational excellence, and shareholder returns through disciplined financial management.